QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.

Recent Findings in Prostate Cancer Research

European Study: PSA Testing Reduces Prostate Cancer Deaths Recent results from the European Randomized Study of Screening for Prostate Cancer showed that PSA-based screening lowered the risk of prostate cancer mortality by 32% for men who were 55-69 years old…

Read More
article10.1 13

Underreporting of Robotic-Assisted Surgery Complications

A study published online in the Journal for Healthcare Quality examined the reporting system for robotic-assisted surgery complications. The researchers cross-referenced reports of robotic-assisted surgery complications in legal documents and the news media with the FDA database of adverse events….

Read More
article9.1 14

The Growing Evidence Supporting Mid-life PSA Testing

Yet, due to the possible overdiagnosis and overtreatment of non-life threatening cancers, the use of routine PSA testing has become controversial. However, a recent study from Memorial Sloan-Kettering Cancer Center added to the growing body of evidence supporting the value…

Read More

Cancer Detection Tool Saves Lives

The LUGPA’s position on PSA screening is: Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being…

Read More
article7.1 12

Going the Distance

Since 1968, Chuck Koeppen has been helping students achieve their athletic goals as a cross country and track coach. His enthusiasm for coaching is evident. “It’s an incredible job,” he said. “I have a passion for the sport, but it’s…

Read More
article6.1 12

Developments in Prostate Cancer Treatment

Shorter-term Hormone Therapy For patients with high-risk prostate cancer, the current recommended duration of androgen deprivation therapy (ADT), also known as hormone therapy, is 24-36 months. However, researchers at the annual Genitourinary Cancers Symposium compared patients treated with ADT for…

Read More

Subscribe to Quest

"*" indicates required fields

Email

This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*
Address*